(UNH) UnitedHealth - Ratings and Ratios
Insurance, Care Delivery, Analytics, Pharmacy Services
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.28% |
| Yield on Cost 5y | 3.48% |
| Yield CAGR 5y | 14.08% |
| Payout Consistency | 96.0% |
| Payout Ratio | 42.3% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 41.6% |
| Value at Risk 5%th | 50.6% |
| Relative Tail Risk | -26.14% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.05 |
| Alpha | -51.70 |
| CAGR/Max DD | -0.22 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.602 |
| Beta | 0.269 |
| Beta Downside | 0.110 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.39% |
| Mean DD | 16.70% |
| Median DD | 10.57% |
Description: UNH UnitedHealth September 24, 2025
UnitedHealth Group (NYSE: UNH) is a diversified health-care company headquartered in Eden Prairie, Minnesota, operating globally through four primary segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx.
The UnitedHealthcare segment delivers consumer-oriented health-benefit plans to a broad spectrum of customers-including large national employers, public-sector entities, mid-size and small businesses, and individuals-while also providing Medicare Advantage, Medicaid, and Children’s Health Insurance Program (CHIP) coverage to underserved populations.
Optum Health focuses on care delivery and management services, offering wellness programs, consumer engagement tools, and health-financial solutions to patients, providers, employers, payers, and government agencies.
Optum Insight supplies software, data analytics, advisory consulting, and managed-service outsourcing to hospitals, physicians, health plans, life-science firms, and governmental bodies, positioning the business as a key enabler of value-based care.
Optum Rx administers pharmacy-care services, including retail network contracting, home delivery, specialty pharmacy, infusion services, and formulary-management programs such as step therapy and drug-adherence initiatives.
**Key recent metrics (FY 2024):**
• Total revenue ≈ $324 billion, up ~6% YoY, driven by enrollment growth in Medicare Advantage (≈ 30 million members) and expanding Optum services.
• Operating margin ≈ 6.2%, reflecting disciplined cost control amid rising health-care inflation (~4.5% YoY).
• Free cash flow generation of roughly $15 billion, supporting a ~ 19% dividend yield and ongoing share-repurchase program.
**Sector drivers:** The aging U.S. population and the shift toward value-based reimbursement models are fueling demand for integrated care solutions, a niche where UnitedHealth’s Optum platforms have a competitive edge. Conversely, regulatory risk-particularly potential changes to Medicare Advantage payment rates-remains a material uncertainty.
For a deeper dive into UNH’s valuation metrics and scenario analysis, the ValueRay platform offers a transparent, data-driven toolkit you may find useful.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (17.59b TTM) > 0 and > 6% of Revenue (6% = 26.11b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 1.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -4.70% (prev -2.36%; Δ -2.34pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 20.96b > Net Income 17.59b (YES >=105%, WARN >=100%) |
| Net Debt (52.93b) to EBITDA (30.52b) ratio: 1.73 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (912.0m) change vs 12m ago -1.94% (target <= -2.0% for YES) |
| Gross Margin 19.70% (prev 22.87%; Δ -3.17pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 141.6% (prev 131.6%; Δ 10.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.51 (EBITDA TTM 30.52b / Interest Expense TTM 4.03b) >= 6 (WARN >= 3) |
Altman Z'' 1.64
| (A) -0.06 = (Total Current Assets 95.07b - Total Current Liabilities 115.53b) / Total Assets 315.27b |
| (B) 0.31 = Retained Earnings (Balance) 97.59b / Total Assets 315.27b |
| (C) 0.09 = EBIT TTM 26.24b / Avg Total Assets 307.29b |
| (D) 0.46 = Book Value of Equity 95.39b / Total Liabilities 209.46b |
| Total Rating: 1.64 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 73.92
| 1. Piotroski 6.50pt |
| 2. FCF Yield 5.27% |
| 3. FCF Margin 3.99% |
| 4. Debt/Equity 0.84 |
| 5. Debt/Ebitda 1.73 |
| 6. ROIC - WACC (= 6.21)% |
| 7. RoE 18.60% |
| 8. Rev. Trend 97.98% |
| 9. EPS Trend -11.17% |
What is the price of UNH shares?
Over the past week, the price has changed by +3.06%, over one month by -10.35%, over three months by +9.78% and over the past year by -44.79%.
Is UNH a buy, sell or hold?
- Strong Buy: 14
- Buy: 6
- Hold: 5
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the UNH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 385.9 | 17% |
| Analysts Target Price | 385.9 | 17% |
| ValueRay Target Price | 313 | -5.1% |
UNH Fundamental Data Overview November 21, 2025
P/E Trailing = 16.1068
P/E Forward = 17.7305
P/S = 0.6434
P/B = 2.9655
P/EG = 1.193
Beta = 0.429
Revenue TTM = 435.16b USD
EBIT TTM = 26.24b USD
EBITDA TTM = 30.52b USD
Long Term Debt = 72.40b USD (from longTermDebt, last quarter)
Short Term Debt = 7.74b USD (from shortTermDebt, last quarter)
Debt = 80.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 52.93b USD (from netDebt column, last quarter)
Enterprise Value = 329.51b USD (279.99b + Debt 80.14b - CCE 30.61b)
Interest Coverage Ratio = 6.51 (Ebit TTM 26.24b / Interest Expense TTM 4.03b)
FCF Yield = 5.27% (FCF TTM 17.37b / Enterprise Value 329.51b)
FCF Margin = 3.99% (FCF TTM 17.37b / Revenue TTM 435.16b)
Net Margin = 4.04% (Net Income TTM 17.59b / Revenue TTM 435.16b)
Gross Margin = 19.70% ((Revenue TTM 435.16b - Cost of Revenue TTM 349.43b) / Revenue TTM)
Gross Margin QoQ = 18.24% (prev 17.93%)
Tobins Q-Ratio = 1.05 (Enterprise Value 329.51b / Total Assets 315.27b)
Interest Expense / Debt = 1.25% (Interest Expense 1.00b / Debt 80.14b)
Taxrate = 21.24% (686.0m / 3.23b)
NOPAT = 20.66b (EBIT 26.24b * (1 - 21.24%))
Current Ratio = 0.82 (Total Current Assets 95.07b / Total Current Liabilities 115.53b)
Debt / Equity = 0.84 (Debt 80.14b / totalStockholderEquity, last quarter 95.79b)
Debt / EBITDA = 1.73 (Net Debt 52.93b / EBITDA 30.52b)
Debt / FCF = 3.05 (Net Debt 52.93b / FCF TTM 17.37b)
Total Stockholder Equity = 94.55b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.58% (Net Income 17.59b / Total Assets 315.27b)
RoE = 18.60% (Net Income TTM 17.59b / Total Stockholder Equity 94.55b)
RoCE = 15.72% (EBIT 26.24b / Capital Employed (Equity 94.55b + L.T.Debt 72.40b))
RoIC = 11.88% (NOPAT 20.66b / Invested Capital 173.93b)
WACC = 5.67% (E(279.99b)/V(360.12b) * Re(7.01%) + D(80.14b)/V(360.12b) * Rd(1.25%) * (1-Tc(0.21)))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.24%
[DCF Debug] Terminal Value 79.83% ; FCFE base≈15.66b ; Y1≈17.52b ; Y5≈23.25b
Fair Price DCF = 445.2 (DCF Value 403.27b / Shares Outstanding 905.8m; 5y FCF grow 13.70% → 3.0% )
EPS Correlation: -11.17 | EPS CAGR: -10.79% | SUE: 0.53 | # QB: 0
Revenue Correlation: 97.98 | Revenue CAGR: 12.10% | SUE: 0.08 | # QB: 0
Additional Sources for UNH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle